Toxicity and bone marrow response of patients with hairy cell leukemia treated with biosynthetic (recombinant) α-2-interferonJACOBS, A. D; NAIEM, F; CHAMPLIN, R. E et al.Blut. 1985, Vol 50, Num 1, pp 33-34, issn 0006-5242Article

Human tolerance and histopathologic effects of long-term administration of intranasal interferon-α2HAYDEN, F. G; MILLS, S. E; JOHNS, M. E et al.The Journal of infectious diseases. 1983, Vol 148, Num 5, pp 914-921, issn 0022-1899Article

Pegylated interferon-α2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysersBARRIL, G; QUIROGA, J. A; SANZ, P et al.Alimentary pharmacology & therapeutics. 2004, Vol 20, Num 1, pp 37-44, issn 0269-2813, 8 p.Article

Fatal exacerbation of chronic hepatitis B induced by recombinant alpha-interferonMARCELLIN, P; COLIN, J.-F; BOYER, N et al.Lancet (British edition). 1991, Vol 338, Num 8770, issn 0140-6736, p. 828Article

Production of subtype-specific antipeptide antibodies to human interferon-α₁ and -α₄SATTAYASAI, N; HIBBS, A. R; MCMULLEN, G. L et al.Journal of interferon research. 1988, Vol 8, Num 3, pp 325-332, issn 0197-8357Article

Treatment of multiple myeloma with recombinant α-interferonQUESADA, J. R; ALEXANIAN, R; HAWKINS, M et al.Blood. 1986, Vol 67, Num 2, pp 275-278, issn 0006-4971Article

Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patientsGOWIN, Krisstina; THAPALIYA, Prakash; CAMORIANO, John et al.Haematologica (Roma). 2012, Vol 97, Num 10, pp 1570-1573, issn 0390-6078, 4 p.Article

Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferonASCIERTO, Paolo A; CHIARION-SILENI, Vanna; MUGGIANO, Antonio et al.Journal of chemotherapy (Testo stampato). 2014, Vol 26, Num 4, pp 193-201, issn 1120-009X, 9 p.Article

Consideration of the cost of interferon alfa-2b in the treatment of basal cell carcinomaSHIELL, A.Australasian journal of dermatology. 1994, Vol 35, Num 2, pp 71-75, issn 0004-8380Article

Complete remission in a patient with acute myelogenous leukemia treated with leukocyte α-interferon and cimetidineANKERST, J; FÄLDT, R; NILSSON, P. G et al.Cancer immunology and immunotherapy. 1984, Vol 17, Num 1, pp 69-71, issn 0340-7004Article

Failure of interferon-alpha 2b in the treatment of mature keloidsAL-KHAWAJAH, M. M.International journal of dermatology. 1996, Vol 35, Num 7, pp 515-517, issn 0011-9059Article

Recombinant interferon α-2b in the treatment of polycythemia veraCIMINO, R; RAMETTA, V; MATERA, C et al.American journal of hematology. 1993, Vol 44, Num 3, pp 155-157, issn 0361-8609Article

Recombinant interferon alpha-2b as treatment of essential thrombocythaemiaRAMETTA, V; FERRARA, F; MAROTTOLI, V et al.Acta haematologica. 1994, Vol 91, Num 3, pp 126-129, issn 0001-5792Article

In vitro data supporting interferon plus cytotoxic agent combinationsVON HOFF, D. D.Seminars in oncology. 1991, Vol 18, Num 5, pp 58-61, issn 0093-7754, SUP7Article

Cortisol stimulation by recombinant interferon-α₂ROOSTH, J; POLLARD, R. B; BROWN, S. L et al.Journal of neuroimmunology. 1986, Vol 12, Num 4, pp 311-316, issn 0165-5728Article

Platelet function and interferon alpha-2a treatment in essential thrombocythaemiaCATANI, L; GUGLIOTTA, L; CASCIONE, M. L et al.European journal of haematology. 1991, Vol 46, Num 3, pp 158-162, issn 0902-4441, 5 p.Article

Traitement des adénocarcinomes rénaux métastatiques par l'association interféron recombinant alpha-2a et vinblastine = Treatment of metastatic renal cell carcinoma with combined recombinant alpha-2a interferon and vinblastineBERGERAT, J. P; DUFOUR, P; OBERLING, F et al.La Presse médicale (1983). 1987, Vol 16, Num 39, pp 1953-1956, issn 0755-4982Article

Combined recombinant human interferon alpha₂ and cytotoxic agents studied in a clonogenic assayWELANDER, C. E; MORGAN, T. M; HOMESLEY, H. D et al.International journal of cancer. 1985, Vol 35, Num 6, pp 721-729, issn 0020-7136Article

Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancerADAMS, F; QUESADA, J. R; GUTTERMAN, J. U et al.JAMA, the journal of the American Medical Association. 1984, Vol 252, Num 7, pp 938-941, issn 0098-7484Article

Reduction in p48-ISGFγ levels confers resistance to Interferon-α_2a in MHCC97 cellsWU, Wei-Zhong; SUN, Hui-Chuan; GAO, Yan-Qin et al.Oncology. 2004, Vol 67, Num 5-6, pp 428-440, issn 0030-2414, 13 p.Article

Immunogenicity of biopharmaceuticals. The european perspectiveSCHELLEKENS, H; CASADEVALL, N.Developments in biologicals. 2003, Vol 112, pp 23-28, issn 1424-6074, 6 p.Article

Mechanisms of interferon-alpha induced apoptosis in malignant cellsTHYRELL, Lena; ERICKSON, Sven; ZHIVOTOVSKY, Boris et al.Oncogene (Basingstoke). 2002, Vol 21, Num 8, pp 1251-1262, issn 0950-9232Article

Alpha interferon treatment of patients with hairy-cell leukaemiaHAGBERG, H; ALM, G; BJORKHOLM, M et al.Scandinavian journal of haematology. 1985, Vol 35, Num 1, pp 66-70, issn 0036-553XArticle

Purification of human leukocyte interferon alpha by carboxymethyl controlled pore glass bead chromatographyMECS, I; CHIN, D; FOX, F et al.Archives of virology. 1984, Vol 81, Num 3-4, pp 303-311, issn 0304-8608Article

Antiviral potency analysis and functional comparison of consensus interferon, interferon-α2a and pegylated interferon-α2b against hepatitis C virus infectionERICKSON, Andrea K; SEIWERT, Scott; GALE, Michael et al.Antiviral therapy (London). 2008, Vol 13, Num 7, pp 851-862, issn 1359-6535, 12 p.Article